ClinicalTrials.gg
CompletedNCT06742086Updated Oct 15, 2025

A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

A Phase 1 interventional study of Venetoclax in Healthy Volunteer, sponsored by AbbVie. Completed at 2 sites in United States. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The objective of this study is to assess the bioavailability (BA) of venetoclax new high drug load hot melt extrusion-03 (HME-03) tablet formulation at two different tablet strengths relative to the commercial venetoclax tablet formulation under high-fat conditions in healthy female volunteers. Additionally, this study will assess the potential food effect on the BA of the venetoclax HME-03 tablet at the highest dosage strength.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • Venetoclax
  • ABT-199
  • Venclexta
  • Venclyxto
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) is 18.0 to 32.0 kg/m\^2.
  • Must either be: , permanently surgically sterile, or perimenopausal or premenopausal and practicing a method of until at least 30 days after the last dose of study drug.
  • Have CD19+ B-cell count > 150 cells/μL at screening.

Exclusion criteria

Exclusion Criteria:

  • History: of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, pulmonary, or hepatic diseases within the past 6 months that in the option of the investigator would adversely affect her participating in this study.
  • History of any sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Stage 1: Sequence 1: Venetoclax

    Participants will receive commercial venetoclax following a high-fat meal (Regimen A), followed by venetoclax hot melt extrusion-03 (HME-03) dose A following a high-fat meal (Regimen B), followed by venetoclax HME-03 dose B following a high-fat meal (Regimen C), finally followed by venetoclax HME-03 dose A following fasting (Regimen D), as part of the approximately 18 month study duration.

    Drug: Venetoclax

  • Experimental
    Stage 1: Sequence 2: Venetoclax

    Participants will receive Regimen B, followed by Regimen C, followed by Regimen A, finally followed by Regimen D, as part of the approximately 18 month study duration.

    Drug: Venetoclax

  • Experimental
    Stage 1: Sequence 3: Venetoclax

    Participants will receive Regimen C, followed by Regimen A, followed by Regimen B, finally followed by Regimen D, as part of the approximately 18 month study duration.

    Drug: Venetoclax

  • Experimental
    Stage 2: Sequence 1: Venetoclax

    Participants will receive Regimen A, followed by Regimen B, finally followed by Regimen C, as part of the approximately 18 month study duration.

    Drug: Venetoclax

  • Experimental
    Stage 2: Sequence 2: Venetoclax

    Participants will receive Regimen B, followed by Regimen C, finally followed by Regimen A, as part of the approximately 18 month study duration.

    Drug: Venetoclax

  • Experimental
    Stage 2: Sequence 3: Venetoclax

    Participants will receive Regimen C, followed by Regimen A, finally followed by Regimen B, as part of the approximately 18 month study duration.

    Drug: Venetoclax

Interventions

  • Oral Tablet

    Also known as: ABT-199, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 18 Months

  2. Maximum Observed Plasma Concentration (Cmax) of Venetoclax Hot Melt Extrusion-03 (HME-03)

    Cmax of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

  3. Time to Cmax (Tmax) of Venetoclax HME-03

    Tmax of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

  4. Apparent Terminal Phase Elimination Constant (β) of Venetoclax HME-03

    β of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

  5. Terminal Phase Elimination Half-Life (t1/2) of Venetoclax HME-03

    t1/2 of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

  6. Area Under the Plasma Concentration-Time Curve from Time 0 Until the Last Measurable Concentration (AUCt) of Venetoclax HME-03

    AUCt of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

  7. Area Under the Plasma Concentration-Time Curve from Time 0 Until Infinity (AUCinf) of Venetoclax HME-03

    AUCinf of venetoclax HME-03.

    Time frame: Up to Approximately 18 Months

07

Study locations

2 sites
  • Acpru /Id# 272979
    Grayslake, Illinois 60030, United States
  • PPD Phase I Clinic /ID# 275754
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Oct 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 19, 2024
StartActual
Dec 19, 2024
Primary completionActual
Oct 8, 2025
CompletionActual
Oct 8, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06742086
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
Dec 19, 2024
Primary completion
Oct 8, 2025
Completion
Oct 8, 2025
Last update
Oct 15, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion